The Food and Drug Administration has accepted Insmed's application seeking full approval of ARIKAYCE, an inhaled antibiotic for Mycobacterium avium complex (MAC) lung disease, and granted it priority review, the company announced Sept. 21. The agency set a target action date of Jan. 28, 2027.
This is a regulatory milestone, not a new approval. But it matters for patients who cannot get the drug today. ARIKAYCE's current label covers only adults with limited treatment options whose infections did not clear after at least six months of standard multidrug therapy. The new application is based on a trial in people with a new MAC infection who had not yet received antibiotics, and it could move the drug earlier in treatment if the FDA agrees.
